Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib (JAK1 Inhibitor): Atopic Dermatitis
- Braftovi® (encorafinib) + Erbitux® (cetuximab): 1st line BRAF-mutant Metastatic Colorectal Cancer
- Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab): BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
- COVID-19 Vaccine: COVID-19 Infection (in collaboration with BioNTech)
- Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX): Hemophilia
- Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy): Duchenne Muscular Dystrophy
- Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII): Hemophilia
- Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor): Hemophilia
- Prophylactic Vaccine: Clostridioides difficile infection
- Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal infections (adult, pediatric)
- Prophylactic Vaccine: Meningococcal Infections (adolescent and young adults)
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
- Relugolix combination: Uterine Fibroids, Endometriosis
- Ritlecitinib (JAK3/TEC Inhibitor): Alopecia Areata
- Sasanlimab (PF-06801591) + BCG: Non-Muscle-Invasive Bladder Cancer
- Somatrogon (PF-06836922): Growth Hormone Deficiency (adult, pediatric)
- Talzenna® (talazoparib) + Xtandi® (enzalutamide): 1st Line Metastatic Castration-Resistant Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
- Xtandi® (enzalutamide): Non-metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of May 4, 2021
- Discovery Projects
- 30Phase 1
- 38Phase 2
- 22Phase 3
- 10Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-07304814 Therapeutic Area: Hospital (Anti-Infectives) Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: SARS-CoV-2 3CL protease inhibitor (IV anti-viral) | COVID-19 Infection | Phase 1 | New Molecular Entity | Small Molecule |
PF-07321332 Therapeutic Area: Hospital (Anti-Infectives) Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: SARS-CoV-2 3CL protease inhibitor (oral anti-viral) | COVID-19 Infection
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-07242813 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: CD1a molecule (CD1A) inhibitor | Atopic Dermatitis (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06835375 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Chemokine Inhibitor | Lupus (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07054894 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CCR6 Antagonist | Inflammatory Bowel Disease | Phase 1 | New Molecular Entity | Small Molecule |
danuglipron (PF-06882961) + PF-06865571 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor | Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-06842874 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 4,6 Inhibitor | Pulmonary Arterial Hypertension | Phase 1 | New Molecular Entity | Small Molecule |
PF-06946860 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody | Cachexia (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07258669 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Melanocortin-4 receptor (MC4R) Antagonist | Anorexia
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-07081532 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist | Diabetes Mellitus-Type 2 and Obesity | Phase 1 | New Molecular Entity | Small Molecule |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta® (axicabtagene ciloleucel)forCancer(Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Small Molecule |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
